Open access
Plasma p‐tau217 detects Alzheimer's disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort
A. Fernández-Lebrero
J. Jiménez-Balado
G. García‐Escobar
José Contador
Isabel Estragués‐Gázquez
Laia Peraferrer-Montesinos
Rosa-María Manero-Borràs
L. Gramegna
M. Viles
A. R. Campello
P. Ortiz-Romero
M. De Diego
M. del Campo
J. Torres‐Torronteras
E. Jiménez‐Moyano
H. Blasco‐Forniés
M. Suárez-Calvet
Á. Ois
Albert Puig-Pijoan
I. Navalpotro‐Gómez
Medicine
Abstract
Cerebral amyloid angiopathy (CAA) frequently co‐occurs with Alzheimer's disease (AD), generating mixed vascular–neurodegenerative phenotypes. Plasma phosphorylated tau (p‐tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear.